Latest news

Posters presentation with Novadiscovery and Calvagone at the PAGE Meeting

ENYO Pharma is pleased to collaborate with Novadiscovery and Calvagone which will present the first in silico liver disease model and the pharmackinetics-pharmacodynamics analysis respectivelly of EYP001 treatment effect on Hepatitis B virus (HBV) infected patients at the PAGE Meeting, May 29th – June 1st, 2018 in Switzerland.

Poster with Novadiscovery

Poster with Calvagone

Read more »

MIMESIS Newsletter #3: A novel systems biology approach to develop preclinical assets

MIMESIS NEWSLETTER #3, April 2018

A novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses.

MIMESIS is a research and innovation project coordinated by ENYO Pharma and funded under the highly selective H2020 – SMEInstrument – Phase 2 call that aims at: “Dedicated support to biotechnology SMEs closing the gap from lab to market”. The MIMESIS project was launched on Nov 2016 for 2 years.

Read more »

USA allowance for the FXR agonist use patent in HBV

ENYO Pharma got the USA allowance for its FXR agonist use patent in hepatitis B virus (HBV). The patent was licensed under exclusive agreement from Inserm. FXR agonists change the composition of the transcriptional complex on the HBV cccDNA resulting in repression of HBV cccDNA expression.

Read more »

MIMESIS Newsletter #2: A novel systems biology approach to develop preclinical assets

MIMESIS NEWSLETTER #2, December 2017

A novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses.

MIMESIS is a research and innovation project coordinated by ENYO Pharma and funded under the highly selective H2020 – SMEInstrument – Phase 2 call that aims at: “Dedicated support to biotechnology SMEs closing the gap from lab to market”. The MIMESIS project was launched on Nov 2016 for 2 years.

Read more »

Collaboration with Imperial College to evaluate EYP001 in patients with BAD

ENYO Pharma is pleased to announce the initiation of a research collaboration with Professor Julian Walters at Imperial College London. The main goal of these investigations is to evaluate the potential for therapeutic use of the FXR agonist EYP001 in patients with primary bile acid diarrhoea. Primary Bile Acid Diarrhoea (BAD) is a common form of chronic diarrhoea associated with excessive faecal bile acid (BA) loss in the absence of overt ileal disease. Explants of human ileum from healthy subjects will be exposed to increasing concentrations of ENYO Pharma’s FXR agonist.

Read more »